Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms

abstract

  • The combination of temsirolimus and bevacizumab had substantial activity and reasonable tolerability in a multicenter phase II trial, with RR of 41%, well in excess of single targeted agents in patients with progressive PNETs. Six-month PFS was a notable 79% in a population of patients with disease progression by RECIST criteria within 7 months of study entry. On the basis of this trial, continued evaluation of combination mTOR and VEGF pathway inhibitors is warranted.

publication date

  • May 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4417726

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.56.2082

PubMed ID

  • 25488966

Additional Document Info

start page

  • 1551

end page

  • 6

volume

  • 33

number

  • 14